Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia (Q40131183)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 May 2007

Language	Label	Description	Also known as
English	Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia	scientific article published on 18 May 2007

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

Andreas Strasser

3

1 reference

Europe PubMed Central

17 September 2017

author name string

Kuroda J

1

1 reference

Europe PubMed Central

17 September 2017

Kimura S

2

1 reference

Europe PubMed Central

17 September 2017

Andreeff M

4

1 reference

Europe PubMed Central

17 September 2017

O'Reilly LA

5

1 reference

Europe PubMed Central

17 September 2017

Ashihara E

6

1 reference

Europe PubMed Central

17 September 2017

Kamitsuji Y

7

1 reference

Europe PubMed Central

17 September 2017

Yokota A

8

1 reference

Europe PubMed Central

17 September 2017

Kawata E

9

1 reference

Europe PubMed Central

17 September 2017

Takeuchi M

10

1 reference

Europe PubMed Central

17 September 2017

Tanaka R

11

1 reference

Europe PubMed Central

17 September 2017

Tabe Y

12

1 reference

Europe PubMed Central

17 September 2017

Taniwaki M

13

1 reference

Europe PubMed Central

17 September 2017

Maekawa T

14

1 reference

Europe PubMed Central

17 September 2017

publication date

18 May 2007

1 reference

Europe PubMed Central

17 September 2017

Cell Death & Differentiation

1 reference

Europe PubMed Central

17 September 2017

14

1 reference

Europe PubMed Central

17 September 2017

9

1 reference

Europe PubMed Central

17 September 2017

1667-1677

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.cdd.4402168

0 references

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Drug resistance in cancer: principles of emergence and prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Dynamics of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

BH3-Only proteins-essential initiators of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Apoptosis signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Phosphorylation of the pro-apoptotic protein Bim in lymphocytes is associated with protection from apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Polycystic kidney disease prevented by transgenic RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

21 January 2018

Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

7 January 2021

based on heuristic

inferred from DOI database lookup

Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

7 January 2021

based on heuristic

inferred from DOI database lookup

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiapoptotic BCL-2 is required for maintenance of a model leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402168

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CDD.4402168

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40131183&oldid=1886432810"